Suppr超能文献

小儿心脏移植后蛋白丢失性肠病复发:多中心病例系列。

Protein-losing enteropathy recurrence after pediatric heart transplantation: Multicenter case series.

机构信息

Division of Pediatric Cardiology, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Division of Pediatric Cardiology, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA.

出版信息

Pediatr Transplant. 2022 Aug;26(5):e14295. doi: 10.1111/petr.14295. Epub 2022 Apr 21.

Abstract

BACKGROUND

Protein-losing enteropathy (PLE) is a devastating complication of the Fontan circulation. Although orthotopic heart transplantation (HTx) typically results in resolution of PLE symptoms, isolated cases of PLE relapse have been described after HTx.

METHODS

Patients with Fontan-related PLE who had undergone HTx at participating centers and experienced relapse of PLE during follow-up were retrospectively identified. Available data related to pre- and post-HTx characteristics and PLE events were collected.

RESULTS

Eight patients from four different centers were identified. Median time from Fontan procedure to the development of PLE was 8 years, and median age at HTx was 17 years (range 7.7-21). In all patients, PLE resolved at a median time of 1 month after HTx (0.3-5). PLE recurrences occurred at a median time of 7.5 months after HTx (2-132). Each occurrence was associated with one or more significant clinical events; most commonly cellular- or antibody-mediated rejection; and less commonly graft dysfunction, infection, thrombosis, and posttransplant lymphoproliferative disease. PLE recurrences resolved after the successful treatment of the concomitant event, after a median time of 2 months in seven cases, while persisted and recurred in one patient in association with atypical mycobacterium infection and subsequent PTLD onset and relapses. Six patients were alive during follow-up at a median time of 4 years (1.3-22.5) after HTx.

CONCLUSIONS

This is the largest series of PLE recurrence after HTx. All cases were associated with one or more concomitant and significant clinical events. PLE typically resolved after resolution of the inciting clinical event.

摘要

背景

蛋白丢失性肠病(PLE)是法洛四联症 Fontan 循环的一种严重并发症。虽然心脏原位移植(HTx)通常可使 PLE 症状得到缓解,但也有报道称 HTx 后 PLE 会复发。

方法

回顾性分析了在参与中心接受 HTx 并在随访期间出现 PLE 复发的 Fontan 相关 PLE 患者。收集了与 HTx 前和后特征及 PLE 事件相关的可用数据。

结果

从四个不同的中心确定了 8 例患者。从 Fontan 手术到 PLE 发生的中位时间为 8 年,HTx 时的中位年龄为 17 岁(范围为 7.7-21 岁)。在所有患者中,PLE 在 HTx 后 1 个月内中位时间得到缓解(0.3-5 个月)。PLE 复发的中位时间为 HTx 后 7.5 个月(2-132 个月)。每次发作均与一个或多个显著的临床事件相关;最常见的是细胞介导或抗体介导的排斥反应;较少见的是移植物功能障碍、感染、血栓形成和移植后淋巴组织增生性疾病。在七个病例中,通过成功治疗伴随的事件,PLE 复发在中位时间 2 个月后得到缓解,而在一个病例中,与非典型分枝杆菌感染和随后的 PTLD 发作及复发相关,PLE 持续存在并复发。在 HTx 后中位时间 4 年(1.3-22.5 年)的随访期间,有 6 例患者存活。

结论

这是 HTx 后 PLE 复发的最大系列。所有病例均与一个或多个伴随的严重临床事件相关。PLE 通常在引发临床事件得到解决后得到缓解。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验